Erythropoietin Market Forecast to 2015
In the biopharmaceutical industry, protein-based therapies have become one of the most effective clinical methods to treat a wide spectrum of diseases, ranging from cancer to metabolic disorders. According to our new research report, the market for Erythropoietin (EPO), a glycoprotein hormone responsible for the regulation of red blood cell production, represents one of the significant segments of the protein therapeutics market. The second-generation EPO, also called darbepoetin, is gaining market share as it allows patients to administer dose at much lower frequency.
The clinical application of EPO lies in the treatment of anemia resulting from chronic renal failure or cancer chemotherapy. The report, “Erythropoietin Market Forecast to 2015”, finds that three types of EPO are commercially available at present, and the US represents the world’s largest market for EPO. Our comprehensive research work also studied the global protein therapeutics market, which is estimated to cross the US$ 143 Billion-mark by 2015-end as new products, especially monoclonal antibodies in the advanced clinical phase, may enter the market.
Our report prudently analyzes the Erythropoietin market, covers the competitive landscape, and evaluates its current and future size. The study of key geographical markets and recent developments have been included in the in-depth research. This way, the extensive study will prove to be a complete source of knowledge and analysis for clients and potential investors.
The clinical application of EPO lies in the treatment of anemia resulting from chronic renal failure or cancer chemotherapy. The report, “Erythropoietin Market Forecast to 2015”, finds that three types of EPO are commercially available at present, and the US represents the world’s largest market for EPO. Our comprehensive research work also studied the global protein therapeutics market, which is estimated to cross the US$ 143 Billion-mark by 2015-end as new products, especially monoclonal antibodies in the advanced clinical phase, may enter the market.
Our report prudently analyzes the Erythropoietin market, covers the competitive landscape, and evaluates its current and future size. The study of key geographical markets and recent developments have been included in the in-depth research. This way, the extensive study will prove to be a complete source of knowledge and analysis for clients and potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GLOBAL PROTEIN THERAPEUTICS MARKET
3.1 Protein Therapeutics Market Vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2015
3.2.1 Market Segmentation
4. ERYTHROPOIETIN MARKET FORECAST TO 2015
4.1 Scientific Insight
4.2 Current and Future Market Analysis to 2015
4.3 By Application
4.4 Key Geographical Markets
4.5 Key Players and Drugs
4.6 Recent Developments
5. KEY PLAYERS
5.1 Roche Group
5.2 Amgen Inc.
5.3 Johnson & Johnson
2. RESEARCH METHODOLOGY
3. GLOBAL PROTEIN THERAPEUTICS MARKET
3.1 Protein Therapeutics Market Vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2015
3.2.1 Market Segmentation
4. ERYTHROPOIETIN MARKET FORECAST TO 2015
4.1 Scientific Insight
4.2 Current and Future Market Analysis to 2015
4.3 By Application
4.4 Key Geographical Markets
4.5 Key Players and Drugs
4.6 Recent Developments
5. KEY PLAYERS
5.1 Roche Group
5.2 Amgen Inc.
5.3 Johnson & Johnson
LIST OF FIGURES
Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2011
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2011-2015
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2011
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2015
Figure 4-1: Global - Erythropoietin Market (Billion US$), 2011-2015
Figure 4-2: Global - Number of Patients on Dialysis (Million), 2009-2011
Figure 4-3: Global - Breakup of Patients on Dialysis by Region (%), 2011
Figure 4-4: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-5: Global - Breakup of New Cancer Cases by Region (%), 2009
Figure 4-6: Global – Share of US in EPO Market (2011)
Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2011
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2011-2015
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2011
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2015
Figure 4-1: Global - Erythropoietin Market (Billion US$), 2011-2015
Figure 4-2: Global - Number of Patients on Dialysis (Million), 2009-2011
Figure 4-3: Global - Breakup of Patients on Dialysis by Region (%), 2011
Figure 4-4: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-5: Global - Breakup of New Cancer Cases by Region (%), 2009
Figure 4-6: Global – Share of US in EPO Market (2011)
LIST OF TABLES
Table 4-1: US - Sales of Key EPO Products (Billion US$), 2009-2011
Table 4-2: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2011
Table 4-3: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2011
Table 4-4: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2011
Table 5-1: Roche - Key Products in Protein Therapeutics
Table 5-2: Amgen Inc. - Key Products in Protein Therapeutics
Table 5-3: Johnson & Johnson - Key Products in Protein Therapeutics
Table 4-1: US - Sales of Key EPO Products (Billion US$), 2009-2011
Table 4-2: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2011
Table 4-3: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2011
Table 4-4: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2011
Table 5-1: Roche - Key Products in Protein Therapeutics
Table 5-2: Amgen Inc. - Key Products in Protein Therapeutics
Table 5-3: Johnson & Johnson - Key Products in Protein Therapeutics
